Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07149857 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
A Phase 2 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT07149857 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 60 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 15 study locations across 4 states.
The verdict
NCT07149857, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Cilta-cel
- DRUG Induction therapy
Study Locations (15)
Other
- Royal Prince Alfred Hospital - Camperdown
- Austin Hospital - Heidelberg
- Fiona Stanley Hospital - Murdoch
- Princess Alexandra Hospital - Woolloongabba
- Hosp. Univ. Germans Trias I Pujol - Badalona
- Hosp Univ Vall D Hebron - Barcelona
- Hosp. Clinic de Barcelona - Barcelona
- Hosp. Univ. 12 de Octubre - Madrid
- Clinica Univ. de Navarra - Pamplona
- Hosp Clinico Univ de Salamanca - Salamanca
- Hosp. Univ. Marques de Valdecilla - Santander
- Hosp. Virgen Del Rocio - Seville
Florida
- Moffitt Cancer Center - Tampa
Iowa
- University of Iowa Hospital and Clinics - Iowa City
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2029-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07149857
The ClinicalTrials.gov registry entry for NCT07149857 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07149857 reports 15 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT07149857 about?
NCT07149857 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel". The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta...
What is the current status of trial NCT07149857?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-03. Estimated completion is 2029-04-06.
What conditions does trial NCT07149857 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT07149857?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Cilta-cel (DRUG), Induction therapy (DRUG).
Who is sponsoring clinical trial NCT07149857?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07149857 being conducted?
This trial has 15 study locations across Florida, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.